Lupin Enters Licensing Agreement for Plasil in Philippines, Brazil

Lupin Limited has entered into an exclusive licensing agreement with Neopharmed Gentili S.p.A, an Italian pharmaceutical company, for the gastroenterology brand Plasil in the Philippines and Brazil. The agreement grants Lupin’s subsidiaries, Multicare Pharmaceuticals in the Philippines and MedQuimica in Brazil, the marketing and promotional rights for Plasil, which is used to treat nausea and vomiting. This strategic move is part of Lupin’s efforts to expand its presence in emerging markets.

The financial terms of the agreement have not been disclosed in the filing. However, the arrangement involves Neopharmed overseeing the supply of Plasil in the Philippines, ensuring compliance with global quality standards. In Brazil, the production of Plasil will be shifted to MedQuimica’s manufacturing facility. This operational change is expected to streamline the production process and align with local manufacturing capabilities.

The scope of the agreement includes the marketing and promotion of Plasil in the Philippines and Brazil. Neopharmed will continue to supply the product in the Philippines, while MedQuimica will handle production in Brazil. This collaboration is designed to enhance Lupin’s gastroenterology portfolio and strengthen its market presence in these regions. The agreement also leverages Neopharmed’s distribution network and Lupin’s local expertise to broaden patient access to Plasil.

Plasil is recognized for its efficacy in treating nausea, vomiting, and motility disorders. The agreement with Neopharmed reflects Lupin’s commitment to expanding access to effective treatments in key emerging markets. The collaboration is expected to enhance Lupin’s capabilities in the gastroenterology sector and support its growth strategy in the Philippines and Brazil.

The implementation of this agreement involves Neopharmed managing the supply chain in the Philippines, while MedQuimica will oversee production in Brazil. The transition of production to MedQuimica’s facility is part of the operational plan to ensure efficient manufacturing and distribution of Plasil in the Brazilian market.

Neopharmed Gentili is a pharmaceutical company based in Italy, known for its expertise in mergers and acquisitions and licensing transactions. The company focuses on expanding its international footprint and enhancing its product offerings through strategic partnerships with multinational companies.

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India. The company specializes in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin is committed to improving patient health outcomes and has a strong presence in multiple therapy areas, including gastroenterology, respiratory, cardiovascular, and anti-infective segments.